|
| |
| Camille Loir and Bertrand Groslambert |
| |
| ''The impact of innovation on the profitability of the biotech industry'' |
| ( 2023, Vol. 43 No.3 ) |
| |
| |
| Since the 1970s, advances in biotechnology have rarely translated into profitable financial opportunities. The recent breakthrough in immunotherapy seems to have turned the tide and improved the productivity growth. We study the impact of this innovation on the profitability of the biotech industry. Constructing a new dataset of cancer biotech initial public offerings (IPOs) and using recent observations on the probability of success in the drug development process, we find that the median return on equity in the cancer biotech industry has increased from 11 percent to 15 percent. This is a noticeable improvement but it is not yet sufficient to significantly increase the inflow of early stage investors. The financial constraints in this sector are still important. |
| |
| |
| Keywords: Financing of innovation, Venture capital, Investing, Performance measurement, Asset-backed securities, Simulations, Biotechnology industry, Cost of capital |
JEL: G3 - Corporate Finance and Governance: General
O3 - Technological Change; Research and Development: General |
| |
| Manuscript Received : Jul 19 2022 | | Manuscript Accepted : Sep 30 2023 |
|
